文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

塞尔维亚首例经导管使用Myval Octacor进行瓣中瓣植入术治疗生物人工主动脉瓣功能障碍

First Transcatheter Valve-in-Valve Implantation With Myval Octacor Into a Failed Biological Prosthetic Aortic Valve in Serbia.

作者信息

Jovanovic Valentina Balint, Farkic Mihajlo, Boljevic Darko, Bojic Milovan, Furtula Matija, Topic Dragan, Dobric Milan, Ielasi Alfonso, Zobenica Vladimir, Subotic Ida, Nikolic Aleksandra

机构信息

Dedinje Cardiovascular Institute, Belgrade, Serbia.

School of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.

出版信息

Cardiol Res. 2025 Feb;16(1):72-79. doi: 10.14740/cr1751. Epub 2025 Jan 4.


DOI:10.14740/cr1751
PMID:39897440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11779679/
Abstract

The natural progression of bioprosthetic valve degeneration over time requires further interventions for those experiencing symptomatic prosthesis dysfunction. Transcatheter aortic valve replacement (TAVR) emerges as a promising therapeutic option to alleviate symptoms in such patients. The valve-in-valve (ViV) technique eliminates the necessity for repetitive open-heart surgical procedures, offering particular advantages for individuals with higher surgical risks. In this report, we describe the case of a 78-year-old female patient presenting with severe symptomatic aortic restenosis of a biological aortic valve implanted 5 years prior. Given the patient's high surgical risk, a transcatheter ViV implantation was chosen as the treatment approach. Utilizing a balloon-expandable valve, the intervention resulted in the successful implantation of a functional TAVR, resulting in symptom relief and enabling a fast discharge from the hospital.

摘要

随着时间的推移,生物瓣膜退变的自然进程需要对出现症状性假体功能障碍的患者进行进一步干预。经导管主动脉瓣置换术(TAVR)成为缓解此类患者症状的一种有前景的治疗选择。瓣中瓣(ViV)技术消除了重复进行心脏直视手术的必要性,对于手术风险较高的个体具有特别的优势。在本报告中,我们描述了一例78岁女性患者的病例,该患者在5年前植入的生物主动脉瓣出现严重症状性主动脉瓣再狭窄。鉴于患者手术风险高,选择经导管ViV植入作为治疗方法。使用球囊扩张瓣膜进行干预,成功植入了功能性TAVR,症状得到缓解,患者得以快速出院。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/d0bdd0640211/cr-16-072-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/a9c1b915278d/cr-16-072-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/a3b36b18b42d/cr-16-072-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/4ddcf7512791/cr-16-072-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/d36215a73fa5/cr-16-072-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/e3c5eea08502/cr-16-072-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/d5023b5fd881/cr-16-072-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/d0bdd0640211/cr-16-072-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/a9c1b915278d/cr-16-072-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/a3b36b18b42d/cr-16-072-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/4ddcf7512791/cr-16-072-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/d36215a73fa5/cr-16-072-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/e3c5eea08502/cr-16-072-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/d5023b5fd881/cr-16-072-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c15a/11779679/d0bdd0640211/cr-16-072-g007.jpg

相似文献

[1]
First Transcatheter Valve-in-Valve Implantation With Myval Octacor Into a Failed Biological Prosthetic Aortic Valve in Serbia.

Cardiol Res. 2025-2

[2]
Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience.

Int J Cardiol. 2023-4-1

[3]
A novel balloon-expandable transcatheter aortic valve bioprosthesis: Myval and Myval Octacor.

Expert Rev Cardiovasc Ther. 2024-7

[4]
Angiographic quantification of aortic regurgitation following myval octacor implantation; independent core lab adjudication.

Int J Cardiol. 2023-7-1

[5]
Outcomes Following Transcatheter Aortic Valve Replacement for Degenerative Stentless Versus Stented Bioprostheses.

JACC Cardiovasc Interv. 2019-6-12

[6]
Safety and effectiveness of the novel Myval Octacor transcatheter heart valve in severe, symptomatic aortic valve stenosis - A real-world Indian experience (The OCTACOR India Study).

Cardiovasc Revasc Med. 2024-6

[7]
Recurrent severe aortic stenosis one year after transcatheter aortic valve-in-valve implantation: Successful treatment with balloon aortic valvuloplasty.

J Cardiol Cases. 2016-4-16

[8]
Case report: Transcatheter tricuspid valve-in-valve implantation using novel balloon-expandable aortic valve with 1 year follow-up.

Front Cardiovasc Med. 2023-7-4

[9]
The Myval Balloon-Expandable Transcatheter Heart Valve Implant in Aortic and Mitral Interventions: A Single-Center Experience.

Cureus. 2025-3-15

[10]
Valve-in-valve transcatheter aortic valve implantation with fracturing of a failed small surgical aortic bioprosthesis: a case report.

Eur Heart J Case Rep. 2020-11-19

本文引用的文献

[1]
TAVR for Failed Surgical Aortic Bioprostheses Using a Self-Expanding Device: 1-Year Results From the Prospective VIVA Postmarket Study.

JACC Cardiovasc Interv. 2019-5-27

[2]
Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses: The STS/ACC Registry.

J Am Coll Cardiol. 2018-7-24

[3]
Transcatheter valve-in-valve implantation (VinV-TAVR) for failed surgical aortic bioprosthetic valves.

Clin Res Cardiol. 2018-7-12

[4]
Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves.

Circulation. 2018-1-23

[5]
1-Year Results in Patients Undergoing Transcatheter Aortic Valve Replacement With Failed Surgical Bioprostheses.

JACC Cardiovasc Interv. 2017-5-22

[6]
Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: a PARTNER trial cohort--a analysis.

J Am Coll Cardiol. 2014-9-30

[7]
Transcatheter aortic valve implantation in failed bioprosthetic surgical valves.

JAMA. 2014-7

[8]
Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry.

Circulation. 2012-10-10

[9]
Clinical outcomes of redo valvular operations: a 20-year experience.

Ann Thorac Surg. 2012-8-2

[10]
Patient-prosthesis mismatch in elderly patients undergoing aortic valve replacement: impact on quality of life and survival.

J Heart Valve Dis. 2009-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索